MSL
APLS

Mackay Shields LLC’s Apellis Pharmaceuticals APLS Stock Holding History

Mackay Shields LLC’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-32,400
Closed -$1.39M – 745
2021
Q1 		$1.39M Sell
32,400
-19,700
-38% -$932K 0.01% 907
2020
Q4 		$2.98M Sell
52,100
-9,200
-15% -$389K 0.02% 668
2020
Q3 		$1.85M Buy
61,300
+6,500
+12% +$194K 0.01% 819
2020
Q2 		$1.79M Buy
54,800
+17,100
+45% +$549K 0.01% 809
2020
Q1 		$1.01M Buy
+37,700
New +$1.34M 0.01% 939

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Mackay Shields LLC's APLS Position: Q2 2021 in Review

Mackay Shields LLC sold out of Apellis Pharmaceuticals (APLS) in Q2 2021, closing a stake of 32,400 shares — an estimated $1.39M sold.

Mackay Shields LLC first reported a position in APLS in Q1 2020 and held it in 5 quarters. The position peaked at $2.98M in Q4 2020. 204 funds tracked by Wall St. Rank hold APLS as of Q2 2021.

  • Mackay Shields LLC reported no remaining Apellis Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 32,400 Apellis Pharmaceuticals shares in Q2 2021, an estimated $1.39M.
  • Mackay Shields LLC first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 5 quarters.
  • Mackay Shields LLC's Apellis Pharmaceuticals position peaked at $2.98M in Q4 2020.
  • 204 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.